Pósteres en Congresos Internacionales
AÑO 2023
MDS Foundation 17th International Congress on MDS. Marsella (Francia), 3-6 mayo, 2023.
Sex Determines Differential Genomic Profiles In Chronic Myelomonocytic Leukemia (cmml) Involving Underrepresentation Of Srsf2 Gene Mutation.
X. Calvo, D. Roman-Bravo, N. García-Gisbert, S. García-Ávila, F. López-Cadenas, B. Bellosillo, M. Salido, A. Puiggros, B. Espinet, B. Costan, M. Karasiewicz, A. Rial, L. Florensa, A. Ferrer, L. Arenillas.
Genomic Determinants Of Dysmyelopoiesis And Evaluation Of Its Prognostic Impact In Chronic Myelomonocytic Leukemia (CMML).
X. Calvo, D. X. Calvo, D. Roman-Bravo, N. García-Gisbert, S. García-Ávila, F. López-Cadenas, B. Bellosillo, M. Salido, A. Puiggros, B. Espinet, R. Navarro, M.D.L.A. Manrique, A. Rial, L. Florensa, A. Ferrer, L. Arenillas.
Genomic classification of myelodysplastic syndromes.
Elsa Bernard, Phd, Robert P. Hasserjian, Md, Peter L. Greenberg, Md, Juan E. Arango Ossa, Ms, Maria Creignou, Md, Yasuhito Nannya, Md, Phd, Heinz Tuechler, Juan S. Medina-martinez, Ms, Max Levine, Ms, Martin Jädersten, Md, Phd, Ulrich Germing, Md, Guillermo Sanz, Md, Phd, Arjan A. Van De Loosdrecht, Md, Phd, Olivier Kosmider, Md, Phd, Matilde Y. Follo, Phd, Felicitas Thol, Md, Lurdes Zamora, Phd, Ronald F. Pinheiro, Phd, Andrea Pellagatti, Phd, Harold K. Elias, Md, Detlef Haase, Md, Phd, Christina Ganster Phd, Lionel Ades, Md, Phd, Magnus Tobiasson, Md, Phd, Laura Palomo, Phd, Matteo Giovanni Della Porta, Md, Pierre Fenaux, Md, Phd, Monika Belickova, Phd, Michael R. Savona, Md, Virginia M. Klimek, Md, Fabio P. S. Santos, Md, Phd, Jacqueline Boultwood, Phd, Ioannis Kotsianidis, Md, Phd, Valeria Santini, Md, Francesc Solé, Phd, Uwe Platzbecker, Md, Michael Heuser, Md, Peter Valent, Md, Carlo Finelli, Md, Maria Teresa Voso, Md, Lee-yung Shih, Ms?, Michaela Fontenay, Md, Phd, Joop H. Jansen, Phd, José Cervera, Md, Phd, Norbert Gattermann, Md, Benjamin L. Ebert, Md, Phd, Rafael Bejar, Md, Phd, Luca Malcovati, Md, Mario Cazzola, Md, Seishi Ogawa, Md, Phd, Eva Hellström-lindberg, Md, Phd, Elli Papaemmanuil, Phd.
Umbrella Project: unified platform for a better integral evaluation of MDS.
T. Jiménez Solas, S.m. Toribio Castelló, S. Muntión Olave, T. Gonzalez, M. Del Rey, E. Lumbreras, M. García Antúnez, I. Rodríguez Iglesias, S. González Briones, A. Avendaño Pita, F. López-cadenas, A. Yeguas, D. Valcárcel, F. Prosper, F. Solé, M. Díez Campelo.
Early onset adult MDS without pre-existing disorders: dominant role of NHEJ DNA-repair pathway deleterious germline variants.
Marina Verdejo-sánchez, Salvador Carrillo-tornel, Tzu Hua Chen-liang, Olga Monpel, Teresa Bernal, Lourdes Hermosín, Marta Santiago, Oriol Calvete, Ana Yeguas, Maria López, María Julia Montoro, José Cervera, Francesc Solé, María Diéz-campelo, David Valcarcel, Andrés Jerez.
Characterization of the transcriptional alterations of patients with del(5q) myelodysplastic syndrome.
Berastegui N, Serrano G, Díaz-mazkiaran A, Huerga S, García-olloqui P, Ainciburu A, Alfonso A, Vilas-zornoza A, San Martin P, Lamo De Espinosa J, Acha P, Jimenez T, Molero A, Montoro Mj, Díez-campelo M, Valcarcel D, Solé F, Ochoa I, Hernáez M, Ezponda T, Prósper F.
TP53 allelic state did not influence the prognosis in myelodysplastic syndromes (MDS) with 5q deletion.
Maria Julia Montoro, Laura Palomo, Claudia Haferlach, Francisco Fuster-tormo, Manja Meggendorfer, Blanca Xicoy, Felicitas Isabel Schulz, Mateo Della Porta, Teresa González, Félix López-cárdenas, Pamela Acha, María Díez-campelo, Andrés Jerez, Esperanza Such, Teresa Bernal, Valeria Santini, Uwe Platzbecker, Ulrich Germing, Francesc Solé, Torsten Haferlach, David Valcárcel.
Single-Cell multiomics analysis of myelodysplastic syndrome predicts clinical response to DNA methylation inhibitor therapy.
Ignacio Campillo-marcos, Marta Casado-pelaez, Veronica Davalos, Caterina Mata, Elisabetta Mereu, David Valcárcel, Antonieta Molero, Lurdes Zamora, Laura Palomo, Pamela Acha, Ana Manzanares, Francesc Solé, Manel Esteller.
Clinical and molecular characterization of patients with TRMN.
Oriol Calvete, Julia Mestre, Ana Manzanares, Blanca Xicoy, Lurdes Zamora, Silvia Marcé, Marta Cabezón, Javier Grau, Isabel Granada, Esperanza Such, Laura Palomo, Julia Montoro, Maria Vahí, Leonor Arenillas, Maria Diez-campelo, Felipe Prosper, Francesc Solé.
Longitudinal prevalence of CHIP inbreast and ovarian cancer patients prior and after cytotoxic treatment.
Oriol Calvete, Julia Mestre, Ana Manzanares, Aida Silverio, Rocío Ruiz, Jessica Aranda, Pamela Acha, Laura Palomo, Ana Perez, Beatriz Cirauqui, Vanesa Quiroga, Eudald Felip, Milana Bergamino, Mireia Margeli, Margarita Romeo, Anna Martinez-cardús, Iris Teruel, Francesc Solé.
Analysis of clonal evolution um myelodysplastic syndromes using DNA-single cell.
Pamela Acha, Giulia Maggioni, Elena Saba, Elena Riva, Alessia Campagna, Shahram Kordasti, Laura Palomo, Mar Mallo, Oriol Calvete, Matteo Della Porta, Francesc Solé:analysis.
Genomic and transcriptomic characterization of myelodysplastic syndromes/myeloproliferative neoplasms
Pamela Acha, Teresa Ezponda, Amaia Vilas-zornoza, Blanca Xicoy, Laura Palomo, Francisco Fuster-tormo, Ana Manzanares, Nerea Berastegu2, Lurdes Zamora, Andrés Jerez, Félix López Cadenas, María Diez Campelo, Nicolas Bonadies, José Cervera Zamora, Martí Mascaró, María Julia Montoro, Francisca Hernández, José María Raya, Idoya Ancín, María Vahí, María Paz Garrastazul, María Lourdes Hermosín Ramos, Mar Mallo, Javier Grau, Silvia Marcé, Marta Cabezón, Felipe Prosper, Francesc Solé.
Analysis of clonal evolution in myelodysplastic syndromes using DNA-single cell analysis.
Pamela Acha, Giulia Maggioni, Elena Saba, Elena Riva, Alessia Campagna, Shahram Kordasti, Laura Palomo, Mar Mallo, Oriol Calvete, Matteo Della Porta, Francesc Solé.
Genomic and transcriptomic characterization of myelodysplastic syndromes/myeloproliferative neoplasms.
Pamela Acha, Teresa Ezponda, Amaia Vilas-Zornoza, Blanca Xicoy, Laura Palomo, Francisco Fuster-Tormo, Ana Manzanares, Nerea Berastegui, Lurdes Zamora, Andrés Jerez, Félix López Cadenas, María Diez Campelo, Nicolas Bonadies, José Cervera Zamora, Martí Mascaró, María Julia Montoro, Francisca Hernández, José María Raya, Idoya Ancín, María Vahí, María Paz Garrastazul, María Lourdes Hermosín Ramos, Mar Mallo, Javier Grau, Silvia Marcé, Marta Cabezón, Felipe Prosper, Francesc Solé.
AÑO 2022
64th ASH Annual Meeting and Exposition. New Orleans, Lousiana (USA). 7-10 diciembre, 2022
ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder.
Salvador Carrillo-Tornel1*, Tzu Hua Chen-Liang, MD PhD2*, Ana Yeguas Bermejo3*, Helena Pomares, PhD4*, Alessandro Liquori, PhD5*, Teresa González6*, Teresa Bernal del Castillo7*, Marta Santiago8*, Félix López Cadenas, MD9*, Bernardo López Andrade, MD10*, Raul Teruel Montoya, PhD11*, Esperanza Such, PhD12*, Francisca Maria Hernandez, DM13*, Blanca Xicoy, MD14*, Montserrat Arnan Sangerman, PhD15*, Francesc Solé, PhD16, Jose Cervera, MD, PhD17*, Maria Diez-Campelo, MD18* and Andres Jerez, MD, PhD19*.
Multiplex CRISPR/Cas9 gene editing in human stem cells to model clonal competition in GATA2 Deficiency
Damia Romero-Moya, Oskar Marin-Bejar, Maximiliano Distefano, Joan Pera, Julio Castaño, Jessica Gonzales, Lili Kotmayer, Csaba Bödör, Albert Català, Marcin Wlordaski, Anna Bigas, Alessandra Giorgetti.
Myelodysplastic Syndromes Presenting With Isolated Thrombocytopenia: A Less Aggressive Form Of Presentation And With Better Prognosis.
Ms. Flores-Morán , L. Arenillas , A. Ferrer , F. Lopez-Cadenas , S. Garcia-Avila , C. Fernandez , A. Salar And X. Calvo. Hospital Del Mar, Barcelona, Spain
Characterization of Transcriptional Alterations Leading to Aberrant Myeloid Differentiation in Myelodysplastic Syndromes
Aintzane Diaz-Mazkiaran, MSc, Jesús De la Fuente, MSc, Guillermo Serrano, BSc, Paula Garcia-Olloqui, PhD, Nerea Berastegui, Marina Ainciburu, MSc, Ana Alfonso Pierola, MD, Amaia Vilas-Zornoza, PhD, Patxi San Martin-Uriz, PhD, Jose Maria Lamo De Espinosa, Mikel San Julián, Pamela Acha, Francesc Solé, PhD, Tamara Jimenez, Félix López Cadenas, MD, Maria Diez-Campelo, MD, Antonieta Molero, MD, Maria Julia Montoro, MD, PhD, David Valcarcel, MD, PhD, Teresa Ezponda, Mikel Hernáez, PhD, Felipe Prosper, MD.
Subclonal Kit D816v Mutations Are Prevalent In Chronic Myelomonocytic Leukemia And Correlate With Distinct Phenotypic Features.
Anthony Hunter, Hannah Newman, Eric Solary, Klaus Geissler, Laura Palomo, Francesc Sole, Valeria Santini, Timothy Graubert, Swapna Thota, Elizabeth Griffiths, Lisa Pleyer, Felicitas Thol, Rafael Bejar, Tracy George, Eric Padron.
Title: Inferring Aberrant Expression Dynamics Across Early Myeloid Differentiation To Discover Potential Therapeutic Targets In Myelodysplastic Syndromes.
Aintzane Díaz-Mazkiaran, Jesús De La Fuente, Guillermo Serrano, Paula Garcia-Olloqui, Nerea Berastegui, Marina Ainciburu, Ana Alfonso, Amaia Vilas-Zornoza, Patxi San Martin, Jose Lamo De Espinosa, Mikel San Julián, Pamela Acha, Francesc Solé, Tamara Jimenez, Félix López, María Díez-Campelo, Antonieta Molero, María Julia Montoro, David Valcarcel, Teresa Ezponda, Mikel Hernaez, Felipe Prósper
Incidence, Clinical Associations, And Co-Mutation Patterns Of Uba1 Mutations In Mds.
Maria Sirenko, Elsa Bernard, Ph.D., David Beck, M.D., Ph.D., Maria Creignou, M.D., Dylan Domenico, B.S., Andrea Farina, Ph.D., Juan E. Arango Ossa, M.S., Olivier Kosmider, M.D., Ph.D., Robert P. Hasserjian, M.D., Martin Jädersten, M.D., Ph.D., Ulrich Germing, M.D., Guillermo Sanz, M.D., Ph.D., Arjan A. Van De Loosdrecht, M.D., Ph.D., Matilde Y. Follo, Ph.D., Felicitas Thol, M.D., Lurdes Zamora, Ph.D., Ronald F. Pinheiro, Ph.D., Andrea Pellagatti, Ph.D., Harold K. Elias, M.D., Detlef Haase, M.D., Ph.D., Christina Ganster, Ph.D., Lionel Ades, M.D., Ph.D., Magnus Tobiasson, M.D., Ph.D., Laura Palomo, Ph.D., Matteo Giovanni Della Porta, M.D., Kety Huberman, B.S., Pierre Fenaux, M.D., Ph.D., Monika Belickova, Ph.D., Michael R. Savona, M.D., Virginia M. Klimek, M.D., Fabio P. S. Santos, M.D., Ph.D., Jacqueline Boultwood, Ph.D., Ioannis Kotsianidis, M.D., Ph.D., Valeria Santini, M.D., Francesc Solé, Ph.D., Uwe Platzbecker, M.D., Michael Heuser, M.D., Peter Valent, M.D., Carlo Finelli, M.D., Maria Teresa Voso, M.D., Lee-Yung Shih, M.S., Seishi Ogawa, M.D., Ph.D., Michaela Fontenay, M.D., Ph.D., Joop H. Jansen, Ph.D., José Cervera, M.D., Ph.D., Benjamin L. Ebert, M.D., Ph.D., Rafael Bejar, M.D., Ph.D., Peter L. Greenberg, M.D., Norbert Gattermann, M.D., Luca Malcovati, M.D., Mario Cazzola, M.D., Eva Hellström-Lindberg, M.D., Ph.D., And Elli Papaemmanuil, Ph.D.
Clinical Implications Of P53 Dysfunction In Patients With Myelodysplastic Syndromes.
Elena Riva, Matteo Zampini, Alberto Termanini, Lorenzo Dall’olio, Alessandra Merlotti, Austin Kulasekararaj, Michela Calvi, Clara Di Vito, Daoud Rahal, Arturo Bonometti, Giorgio Croci, Emanuela Boveri, Umberto Gianelli, Maurilio Ponzoni, Antonio Russo, Benedetta Tinterri, Francesca Re, Elisabetta Sauta, Elena Saba, Erica Travaglino, Marta Ubezio, Alessia Campagna, Luca Lanino, Giulia Maggioni, Cristina A Tentori, Chiara Milanesi, Nicla Manes, Saverio D’amico, Francesca Ficara, Laura Crisafulli, Domenico Mavilio, Enrico Lugli, Armando Santoro, Maria Diez-Campelo, Guillermo Sanz, Francesc Solé, Uwe Platzbecker, Valeria Santini, Shahram Kordasti, Pierre Fenaux, Torsten Haferlach, Daniel Remondini, Gastone Castellani, And Matteo G Della Porta, On Behalf Of Genomed4all Consortium (Genomics And Personalized Medicine For All Through Artificial Intelligence In Haematological Diseases – Www.Genomed4all.Eu).
Wt1 Mrna Upregulation In Acute Myeloid Leukemia (Aml) In Complete Molecular Remission (Mcr): Understanding The Limitations And Potential Advantages Of Wt1 As A Measurable Residual Disease (Mrd) Target.
Albert Esquirol, Yolanda Guillen, Elena Bussaglia, Vanesa Criado, Maite Carricondo, Pamela Acha, Manel Esteller, Jorge Sierra, Francesc Solé, Anna Bigas, Josep F. Nomdedéu.
Tp53 Allelic State In Myelodysplastic Syndromes With 5q Deletion.
Maria Julia Montoro, Laura Palomo, Pablo Vidal, Francesc Solé, Esperanza Such, Francisco Fuster-Tormo, Teresa González, Margarita Ortega, Félix López, Sara García-Avila, Nieves García-Gisbert, Eugenia Rivero, María Díez-Campelo, Andrés Jerez, Francesc Bosch, David Valcárcel
Inter-Laboratory Comparison Study Of Optical Genome Mapping Analysis For Cytogenomic Characterization Of Hematological Malignancies: A Spanish Multi-Center Study.
Anna Puiggros, Mar Mallo, Marta Salido, Ana Gómez-García, Rocío García-Serra, Adela Cisneros, Celia González, Gayane Avestisyan, María Rodríguez-Rivera, Alvaro Díaz, Isabel Granada, Esperanza Such, Eulàlia Genescà, Rosa Collado, Manuel Ramírez-Orellana, Francesc Solé, Blanca Espinet.
Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
Sofía M Toribio Castelló, Felix Lopez-Cadenas, MD, Claude Preudhomme,PharmD, PhD, Angela Villaverde Ramiro, Laurène Fenwarth, MD, PhD,Eva Lumbreras, Teresa González, Mónica Del Rey, Blanca Xicoy,MD, Aline Renneville, MD, PhD, Joaquín Sánchez-Garcia, MD,Rosa Coll, MD, Bohrane Slama, José Ángel Hernández-Rivas, MD, PhD, Sylvain Thepot, Teresa Bernal, MD, PhD, Agnès Guerci-Bresler, MD,PhD, Katharina Götze, Jesús María Hernández-Rivas, MD, PhD, Pierre Fenaux, MD, PhD, Consuelo Del Cañizo, MD, PhD and Maria Diez-Campelo, MD, PhD
TP53 Allelic state in del 5Qmds
Maria Julia Montoro, Laura Palomo, Pablo Vidal, Francesc Solé, Esperanza Such, Francisco Fuster-Tormo, Teresa González, Margarita Ortega, Félix López, Sara García-Avila, Nieves García-Gisbert, Eugenia Rivero, María Díez-Campelo, Andrés Jerez, Francesc Bosch, David Valcárcel
EHA 2022 Congress (Hybrid). Viena (Austria). 9-12 junio, 2022
Factors Driving Treatment Decision In Patients With Intermediate-Risk Myelodysplastic Syndrome (Mds): A Retrospective Analysis From The Grupo Español De Síndromes Mielodisplásicos Spanish Mds Registry
María Díez Campelo, David Valcárcel , Jordi Curto , Antonieta Guliana Molero Yordi , Guillermo Sanz Santillana, Andres Jerez, Teresa Cedena, Montserrat Arnan, Marina Diaz BEya, Mar Tormo, L. Hernandez Donoso, Sasse, Emma Colicino, Silvia
Treatment Patterns and Overall Survival in Patients with Intermediate-Risk Myelodysplastic Syndrome (MDS): A Retrospective Analysis in the Grupo Español de Síndromes Mielodisplásicos (GESMD) Spanish MDS Registry
María Díez-Campelo,1-3 Luis E. Benlloch,2 Emma Sasse,4 David Wormser,4 Leyla Hernandez Donoso,4 Silvia Colicino,4 Teresa Bernal,5 Antonieta Molero Yordi,6 Mar Tormo,2,7,8 Montserrat Arnan Sangerman,9 Guillermo Sanz,3,10 Marina Díaz-Beyá,11 María Teresa Cedena Romero,12 Andrés Jerez,13 Brayan Merchán,14 David Valcárcel Ferreiras2,5
ESH 8th Translational Research Conference: MYELODYSPLASTIC SYNDROMES. Virtual. 7-10 abril, 2022
ALLOGENEIC STEM CELL TRANSPLANTATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA. A SINGLE CENTER EXPERIENCE AND DISSECTION OF MUTATIONAL PROFILE
Alejandro Avendaño Pita, Marta Martín-Izquierdo, Ana Yeguas Bermejo, Mónica del Rey, Sofía Toribio Castelló, Sandra Muntión, Tamara Jimenez Solas, Eva Lumbreras Gonzalez, María Cortés Rodríguez, Sara Marcos Asensio, Ana-Africa Martin, M Dolores Caballero, Mónica Cabrero Calvo, Teresa González, Jesús M Hernández-Rivas, María Díez-Campelo
AÑO 2021
Hybrid 9th International Symposium of the European Working Groups of Myelodysplastic Syndromes (EWOG-MDS) and Severe Aplastic Anemia (SAA) in Children and Adolescents. Atenas (Grecia). 10 septiembre – 2 octubre, 2021
Clinical Characteristics, genomic landscape and functional studies of GATA2 deficiency in a cohort of Spanish patients
Damia Romero-Moya, Julio Castaño, Francesca De Giorgio, Francesca Lessi, Paolo Aretini, Chiara Maria Mazzanti, Loris Mularoni, Maximiliano Di Stefano, Alessandro Liquori, Jessica Gonzalez, Emilia J. Kozyra, Albert Catala?, Jose Carlos Rodriguez-Gallego, Josep Nomdedeu, Cristina Di?az de Heredia, Antonio Perez Martinez, Adela Escudero-Lopez, Fe?lix Lo?pez Cadenas, Mari?a Di?ez-Campelo, Teresa Gonza?lez, Carolina Marti?nez-Laperche, Nieves Dorado, Francisco Marco, Jose Cervera, Csaba Bödör, Marcin Wlodarski, Anna Bigas and Alessandra Giorgetti.
MDS Foundation 16th International Congress on MDS. Virtual. 23-26 septiembre,2021
Differencial clinical and mutational profile of Hypoplastic Myelodysplasic Syndromes
F. Hernandez Mohedo, Miguel Ángel Rodríguez Gil M. Bernal Sánchez, Lourdes Hermosín Ramos,Joaquín Sánchez García, María Vahí, Andrés Jerez, F. Solé Ristol, M. Bernal Sánchez, L. Palomo Sanchís, M. Expósito Ruiz, M. Jurado Chacón.
EHA 2021 Congress. Virtual. 9-17 junio, 2021
Myelodysplastic syndrome in young adult without previous organic disfunction: predominance of germline variants in genes of DNA repair pathway and their clinical impact.
Tzu-Hua Chen-Liang, Salvador Carrillo-Tornel, Ana María Hurtado, Marta Santiago, Esperanza Such, Laura Palomo, Miguel Ángel Rodriguez-Gil, María José Jimenez, Rafael del Orbe, Félix López-Cadenas, Mar Tormo, Lourdes Hermosín, Teresa Bernal, Eduardo Salido, Carmen Benet, Begoña Muiña, Raquel Oña, Nuria de Haro, Fernando Ramos, Francisco José Ortuño, Leonor Senent, Esperanza Tuset, Helena Pomares, Antonio Martínez-Francés, Teresa Arquero, Julia Montoro, Raúl Teruel-Montoya, José Cervera, David Valcárcel, Montserrat Arnán, Beatriz Arrizabalaga, María Diez-Campelo, Blanca Xicoy, Francisca Hernandez, Francesc Solé, Guillermo Sanz, Andrés Jerez.
ANALYSIS OF GERMLINE PREDISPOSITION IN PATIENTS WITH MYELOID NEOPLASMS: ASSOCIATION BETWEEN MOLECULAR ALTERATIONS AND CLINICAL HISTORY
Marta Santiago Balsera* , Alessandro Liquori, José Vicente Gil , Gayane Avetisyan, Lourdes Cordón, Beatriz Martín, Elvira Mora, Mariam Ibáñez, Claudia Sargas, Elisa González, Mireia Boluda, Mireya Morote, Cristian García, Cristina Martínez, Alejandra SanJuan, Marta Llop, Pau Montesinos, Eva Barragán, Miguel Ángel Sanz, Guillermo Sanz, Ángel Zúñiga, Esperanza Such, José Cervera»
Cohesin mutations are associated with a poor prognosis phenotype and a worse clinical outcome in low-risk myelodysplastic syndromes patients
Marta Martín Izquierdo; Félix López Cadenas; Javier Sánchez del Real; Alberto Hernández Sánchez; Jesús M Hernández Sánchez; Kamila Janusz; María Díez Campelo; Mar Tormo; Marta Megido; Carmen Olivier; Andrés Madinaveitia Ochoa; Julio Dávila; Magdalena Sierra; Manuel Vargas; Sandra Santos Mínguez; Cristina Miguel García; Rocío Benito; Jesús María Hernández Rivas; Fernando Ramos; María Abáigar.»
«Mesenchymal stromal cells as a potential therapeutic tool in enhancing residual healthy haematopoiesis in low-risk MDS patients
Tamara Jiménez Solas; Sandra Muntión Olave; Félix López Cadenas; Marta Martín Izquierdo; Teresa González Martínez; Kamila Janusz; Teresa Ezponda Itoiz; Alba Vilas Zomoza; Ana Alfonso Pierola; Felipe Prosper Cardoso; Antonieta Molero; David Valcárcel Ferreiras; Fermín Sánchez-Guijo Martín; María Díez Campelo.»
63rd ASH Annual Meeting and Exposition. Atlanta, Georgia (USA). 11-14 diciembre, 2021
Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) «» Is the Threshold of 20% Bone Marrow Blasts Reproducible?
Font, Patricia ; Loscertales , Javier; Muñoz Novas, Carolina; Lopez Rubio, Montserrat; Bermejo, Alfredo; Ricard, Pilar; Seri, Cristina; Soto, Carlos; Garcia Alonso, Luis; Piris Villaespesa, Miguel; Perez Segura, Gloria; Ballesteros, Monica; Benavente, Celina; Gomez Rojas, Sandra; Garcia Herce, Cristina; Castilla, Lucia; Cedena, Teresa; Ortuzar, Ariana; Jimenez Chillon, Carlos; Bellon Jose Maria; Villarubia, Jesus; Diez Martin, Jose Luis
«Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single cell resolution
Marina Ainciburu1,2*, Teresa Ezponda1,2*, Nerea Berastegui1, Ana Alfonso-Pierola2,3, Amaia Vilas-Zornoza1,2, Patxi San Martin-Uriz1,2, Diego Alignani4, Jose Lamo de Espinosa3 Mikel San Julian3, Tamara Jimenez5, F.lix L.pez5, Sandra Muntion5,9, Fermin Sanchez-Guijo5,9, Antonieta Molero6, Julia Montoro6, Guillermo Serrano8, Aintzane Diaz-Mazkiaran2,8, Miren Lasaga7, David Gomez-Cabrero7, Mar.a D.ez-Campelo5, David Valcarcel6, Mikel Hernaez8, Juan P. Romero1,2, §, Felipe Prosper1,2,3,9, §»
Treatment Patterns and Overall Survival in Patients with Intermediate-Risk Myelodysplastic Syndrome (MDS): A Retrospective Analysis in the Grupo Español de Síndromes Mielodisplásicos (GESMD) Spanish MDS Registry
María Díez-Campelo,1-3 Luis E. Benlloch,2 Emma Sasse,4 David Wormser,4 Leyla Hernandez Donoso,4 Silvia Colicino,4 Teresa Bernal,5 Antonieta Molero Yordi,6 Mar Tormo,2,7,8 Montserrat Arnan Sangerman,9 Guillermo Sanz,3,10 Marina Díaz-Beyá,11 María Teresa Cedena Romero,12 Andrés Jerez,13 Brayan Merchán,14 David Valcárcel Ferreiras2,5
Multiple TET2 Mutations as a New Biological Clue for Differentiating Oligomonocytic Chronic Mlomonocytic Leukemia from Myelodysplastic Syndromes.
Nieves Garcia-Gisbert1,2*, Leonor Arenillas, MD, PhD3,4*, David Roman-Bravo, MD3,5*, Juan José Rodríguez-Sevilla, MD5*, Brayan Merchan, MD2,5*, Sara Garcia-Avila, MD2,5*, Concepción Fernández-Rodríguez, PhD2,4*, Joan Gibert, PhD2*, Antonio Salar, MD, PhD2,5*, Beatriz Bellosillo, PhD1,2,4*, Ana Ferrer, MD, PhD3,4* and Xavier Calvo, MD, PhD3,4*
Non-Invasive Genetic Profiling and Monitoring in Myelodysplastic Syndromes
Nieves Garcia-Gisbert, Brayan Merchan, Sara Garcia-Avila, Marta Salido, Concepción Fernández-Rodríguez, Joan Gibert, Lierni Fernández-Ibarrondo, Laura Camacho, Marta Lafuente, Raquel Longarón, Blanca Espinet, Patricia Vélez, Marcio M Andrade-Campos, Ramon M. Pujol, Leonor Arenillas, Xavier Calvo, Carles Besses, Antonio Salar, Beatriz Bellosillos.
Clinical Outcomes of Oligomonocytic Chronic Myelomonocytic Leukemia (OM-CMML) and Predictive Factors of Evolution of OM-CMML into Overt Chronic Myelomonocytic Leukemia (CMML)
16th International Congress on Myelodysplastic Syndromes. Toronto (Canadá) 23-26 septiembre, 2021
Predictive Factors of Oligomonocytic Chronic Myelomonocytic Leukemia (OM-CMML) Evolution to Overt Chronic Myelomonocytic Leukemia (CMML).
AÑO 2020
62nd ASH Annual Meeting and Exposition. Virtual. 5-8 diciembre, 2020
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Iván Martín, Eva Villamón, Rosario Abellán, Mª José Calasanz, Aroa Irigoyen, Guillermo Sanz, Esperanza Such, Elvira Mora, Míriam Gutiérrez, Rosa Collado, Míriam Vara, Mª Laura Blanco, Itziar Oiartzabal, Sara Álvarez, Teresa Bernal, Isabel Granada, Blanca Xicoy, Andrés Jerez, Raquel Fernández, Marisa Calabuig, Francisca García, Alejandro Sanz, Rosana Díez, Ángela Gil, Raquel de Paz, Francisca López, Teresa González, Carlos Solano and Mar Tormo. Spanish Group of Myelodysplastic Syndromes (GESMD). (Pendiente resolución)
Un Índice Pronóstico Internacional Revisado (Ips S-r) De 3.5 Puntos Estratifica A Los Pacientes Con Síndrome Mielodisplásico (Smd) En 2 Grupos De Riesgo
Montoro Maria Julia1, Ortega Margarita1, Villacampa Guillermo2, Bernal Teresa3, Pomares Helena4, Mora Elvira5, Molero Antonieta1, Vilorio Laura3, Tormo Mar6, Díaz-Beyá Marina7, Merchán Brayan8, Jerez Andrés9, Rivero Eugenia10, Lis Maria José11, Cárcel Paula12, Bargay Joan13, Ramos Fernando14, Xicoy Blanca15, Díez-Campelo María16, andValcárcel David1, with the collaboration of the Spanish Group of the Myelodysplastic Syndromes
Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients – Interim Analysis of the European Sintra-REV Trial
Félix López Cadenas, MD , Eva Lumbreras , Blanca Xicoy, MD , Joaquín Sánchez, MD , Rosa Coll, MD , Bohrane Slama, MD , Jose Angel HernandezRivas, MD, PhD , Sylvain Thepot, MD , Teresa Bernal, MD, PhD , Beatriz Arrizabalaga, MD. PhD , Agnès Guerci-Bresler, MD, PhD , Guillermo F Sanz, MD, PhD , Joan Bargay, MD , Maria Luz Amigo, MD , Raquel de Paz, MD , Benet Nomdedeu, MD , Aristoteles Giagounidis , Uwe Platzbecker, MD ,Stefan Wickenhauser , Katharina S. Götze , Ali Arar , Jesus María Hernández Rivas, MD, PhD , Pierre Fenaux, MD, PhD , Consuelo Del Cañizo, MD,PhD and Maria Diez-Campelo, MD, PhD
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)
David P. Steensm1, Martin Wermke, Virginia M. Klimek, Peter L Greenberg, Patricia Font, Rami S. Komrokji, Jay Yang, Andrew M. Brunner, Hetty E. Carraway, Lionel Ades, Aref Al-Kali Juan Manuel Alonso Dominguez, Ana Alonso, Catherine C. Coombs, H. Joachim Deeg, William B. Donnellan, James M. Foran, Guillermo Garcia-Manero, Michael B. Maris, Malgorzata McMasters, Jean-Baptiste Mico1, Jaime Perez De Oteyza, Felicitas Thol, Eunice S. Wang, Justin M. Watts, Silvia Buonamici, Amy Kim, Vikram Gourineni, Alyssa J Marino, Nathalie Rioux, Joanne Schindler, Sherri Smith, Huilan Yao, Xiaobin Yuan, Kun Yu, Uwe Platzbecker.
AÑO 2019
61st ASH Annual Meeting and Exposition. Orlando Florida (USA). 7-9 diciembre, 2019
Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability
Tzu Hua Chen-Liang, Ana M Hurtado López, María Zurdo, Esperanza Such, Raul Teruel-Montoya, PhD, Laura Palomo, María-José Jimenez, MD, Rafael Andres del Orbe Barreto, Blanca Navarro, MD PhD, Félix López Cadenas, MD, Eduardo José Salido, MD, Carmen Benet, MD, Begoña Muiña, Raquel de Oña, Nuria de Haro, Fernando Ramos, MD, MPH, PhD, Montserrat Arnan Sangerman, Francisca Maria Hernandez, MD, Francisco José Ortuño, Leonor Senent, Ana Vicente, María Díez-Campelo, MD, PhD, Maria Lourdes Hermosin, MD, Teresa Bernal Del Castillo, MD, PhD, Mar Tormo, MD, PhD, Beatriz Arrizabalaga, Blanca Xicoy, PhD, José Cervera, MD, PhD, Francesc Sole, PhD, Guillermo F. Sanz, MD, PhD and Andres Jerez
Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group
Lisa Pleyer, Michael Leisch, MD, Alexandra Kourakli, MD, PhD, Eric Padron, MD, Jaroslaw P. Maciejewski, PhD, MD, FACP, Blanca Xicoy, MD, MSc, Jennifer Kaivers, MD, Johanna Ungerstedt, MD, PhD, Sonja Heibl, MD, Peristera Patiou, MD, Anthony M. Hunter, MD, Elvira Mora Casterá, MD, Klaus Geissler, MD, Maria Dimou, MD, PhD, María-José Jimenez, MD, David Kiesl, MD, Nora-Athina Viniou, MD, PhD, Bhumika J. Patel, MD, Montserrat Arnan Sangerman, Peter Valent, MD, Christoforos Roubakis, MD, Teresa Bernal del Castillo, MD, PhD, Athanasios Galanopoulos, MD, PhD, Marisa Calabuig, MD, Nicolas Bonadies, MD, Antonio Medina de Almeida, MD, PhD, Jaroslav Cermak, MD, PhD, Andres Jerez, Julia Montoro, MD, Albert Cortés, Alejandro Avendaño Pita, MD, Bernardo López Andrade, MD, Eva Hellstrom Lindberg, MD, PhD, Ulrich Germing, MD, Mikkael A. Sekeres, MD, MS Alan F. List, MD, Argiris Symeonidis, MD, PhD3 Guillermo F. Sanz, MD, PhD and Richard Greil, MD.
TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (>3 anomalies) Aberrant Karyotypes.
Christina Ganster1, Roxana Schaab1*, Katayoon Shirneshan1*, Lea Naomi Eder1*, Anna Mies2*, Ulrich Germing3*, Ahmet Elmaagacli4*, Francesc Sole5, Laura Palomo5*, Jennifer Kaivers3*, Ulrike Söling6*, Frank Lange7*, Nicolaus Kröger8*, Bernd Hertenstein9*, Konstanze Döhner10*, Gesine Bug11*, Barbara Hildebrandt12*, Marc Talló Parra1*, Maike Nickelsen13*, Bertram Glass14*, Uwe Platzbecker, Md15, Ulrike Bacher16*, Friederike Braulke1*, Julie Schanz1* And Detlef Haase1*.
Molecular Dissection of Del5q: Distinction Between Primary and Secondary Del(5q) and Pathogenetic Implications.
Vera Adema1,2, Laura Palomo2, Cassandra M. Kerr1, Wencke Walter3, Bartlomiej P Przychodzen1, Stephan Hutter3, Thomas Laframboise4, Maria Diez-campelo5, Mar Mallo2, Aziz Nazha6, Blanca Xicoy7, Manja Meggendorfer3, Hetty E. Carraway6, Claudia Haferlach3, Mikkael A. Sekeres6, Valeria Visconte1, Torsten Haferlach3, Francesc Sole2, Jaroslaw P. Maciejewski1
Can Monosomy 7 be Targeted by Next Generation Cereblon-Modulating Agents?
Vera Adema1, Cassandra M. Kerr1, Wencke Walter2, Stephan Hutter2, Yasunobu Nagata1, Hassan Awada1, Sunisa Kongkiatkamon1, Christina Snider1, Milo Co1, Magdalena Rainey1, Arda Durmaz1-3, Manja Meggendorfer2, Aziz Nazha4, Jacob G. Scott1, Hetty E. Carraway4, Mikkael A. Sekeres4, Francesc Sole6, Torsten Haferlach2, Valeria Visconte1, Jaroslaw P. Maciejewski1
Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors.
Adema V, Hershberger C, Walter W, Kerr Cm, Hutter S, Nagata Y, Awada H, Kongkiatkamon S, Snider Ch, Co M, Meggendorfer M, Nazha A, Carraway He, Sekeres Ma, Sole F, Padgett R, Haferlach T, Maciejewski Jp, Visconte V.
Integrated Transcriptomic and Proteomic Analyses of Inflammasome in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
M Zurdo
Transcriptional and gene regulatory networks in the aging-clonal hematopoiesis-myelodysplatic syndromes axis as a tool for identifying novel therapeutic targets.
Dr. Felipe Prosper
Transcriptional regulation of Hematopoietic Stem Cells in Aging and Myelodysplastic Syndrome reveals DDIT3 as a Potential Driver of Transformation.
Teresa Ezponda1,2, Juan P. Romero1,2, Marina Ainciburu1,2, Ana Alfonso2,3, Nerea Berastegui1, Amaia Vilas1,2, Patxi San Martin1,2, Laura Castro1,2, Victoria Riego2,3, Tamara Jimenez4, Félix López4, Jesús M. Hernández4, Antonieta Molero5, Julia Montoro5, Bárbara Tazón5, Bruno Paiva2,6, María Díez-Campelo4, David Valcarcel5, David Lara1,2* and Felipe Prosper2,3*
Transfusion-Dependent Low Risk Myelodysplastic Syndrome (TD LR-MDS): Predictors Ofcardiovascular Events and Death
Marta Alonso Fernández de Gatta, MD PhD , Ana Martín García, MD PhD , Félix López Cadenas, MD , Díaz Peláez Elena, MD , Tamara Jimenez , Jesus Maria . Hernández-Rivas, MD , Victor Vallejo García, MD , Manuel Barreiro Pérez, MD , Lucia Rodríguez Estévez, MD , Juan Carlos Castro Garay , Diego Ávila, MD , Adolfo Alejandro Cabanillas Cabral, MD , Clara Sánchez Pablo, MD , María Díez-Campelo, MD PhD , Pedro Luís Sánchez Fernández, MD PhD.
Morphologic Assessment of Terminal Erythroid Differentiation Predicts Outcomes in Myelodysplastic Syndrome.
Dra. Julia Montoro
EHA 2019 Congress. Amsterdam (Países Bajos). 13-16 junio, 2019
Transcriptional and gene regulatory networks in the aging-clonal hematopoiesis-myelodysplatic syndromes axis as a tool for identifying novel therapeutic targets.
Dr. Felipe Prosper
Transcriptional alterations of hematopoietic stem cells in myelodysplastic syndromes.
Teresa Ezponda1,2, Juan Pablo Romero1,2, Marina Ainciburu1,2, Ana Alfonso2,3, Amaia Vilas1,2, Patxi San Martin1,2, Laura Castro1,2, Tamara Jimenez4, Félix López4, Jesús M. Hernández4, Antonieta Molero5, Julia Montoro5, Barbara Tazón5, Bruno Paiva2,6, Maria Díez-Campelo4, David Valcarcel5, Jesus San Miguel3, David Lara1,2* and Felipe Prosper2,3*
15th International Symposium on Myelodysplastic Syndromes. Copenhague (Dinamarca). 8-11 mayo, 2019
Analysis of the intratumoral heterogeneity in myelodysplastic syndromes associated with del(5q) using a single cell approach.
Pamela Acha, Laura Palomo, Francisco Fuster-Tormo, Blanca Xicoy, Mar Mallo, Paula Gómez-Marzo, Nuri de Haro, Javier Grau, Silvia Marcé, Lurdes Zamora, Francesc Solé.
Pósteres en Congresos Nacionales
AÑO 2020
LXII CONGRESO NACIONAL DE LA SEHH Y XXXVI CONGRESO NACIONAL DE LA SETH. Virtual. 26-30 octubre, 2020
Estudio del impacto pronóstico de la amplitud de distribución eritrocitaria en la supervivencia de los pacientes diagnosticados de síndrome mielodisplásico en el Hospital Son LLàtzer
Herráez Balanzat, Inés ; Del Campo García, Raquel ; Mascaró Riera, Martín ; Cladera Serra, Antonia; Borrás Vives, Jose Bartolo; González Bachs, Elena; Gómez Pérez, Delia; Guerra Hernando, Jose María; Vázquez Fernández , Irene; Amer Salas, Neus; Astudillo Romero, Ivonne Lizett; Bargay Lleonart, Juan Jose
PO-450: análisis de los cambios producidos en el manejo clínico de los pacientes con síndromes mielodisplásicos (SMD) en hospitales españoles con motivo de la pandemia por Covid-19.
Tormo M1, Montoya MC2, Cedena MT3, Calabuig M1, Orero MT4, Jerez A5, Lluch R6, Xicoy B7 ,Recasens V8, Rivero ME9, Amarilla I10, Recio I11, López F12, Marcos J13, Hernandez F14,Carretero M15,De Miguel D16, Benlloch L17, Díez-Campelo M18 con la colaboración del GESMD19
Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of ASXL1 Chromosomal Deletion and Genetic Mutations
iván Martín, Eva Villamón, Rosario Abellán, Mª José Calasanz, Aroa Irigoyen, Guillermo Sanz, Esperanza Such, Elvira Mora, Míriam Gutiérrez, Rosa Collado, Míriam Vara, Mª Laura Blanco, Itziar Oiartzabal, Sara Álvarez, Teresa Bernal, Isabel Granada, Blanca Xicoy, Andrés Jerez, Raquel Fernández, Marisa Calabuig, Francisca García, Alejandro Sanz, Rosana Díez, Ángela Gil, Raquel de Paz, Francisca López, Teresa González, Carlos Solano and Mar Tormo. Spanish Group of Myelodysplastic Syndromes (GESMD).
TRANSLOCACIONES RECÍPROCAS EN SÍNDROMES MIELODISPLÁSTICOS RELACIONADOS CON LA TERAPIA: REVISIÓN DE 69 PACIENTES DE LA BASE DE DATOS DEL GRUPO ESPAÑOL DE SMD CON UN CARIOTIPO EVALUABLE
Grau J1, Costa D2, Nomdedeu M3, Sole F4, Cervera J5, Such E5, Insunza A6, Calasanz MJ7, Oiartazabal I8, Hernandez JM9, Azaceta G10, Alvarez S11, Sanchez J12, Martin ML13, Bargay J14, Gomez V15, Cervero CJ 16, Allegue MJ17, Collado R18, Granada I1.
PAPEL DE LA SOBRECARGA FERRICA EN EL ESTROMA DE LOS SINDROMES MIELODISPLASICOS»
Muntión Olave S1. Jiménez Solas T1. López Cadenas F1, Ortega Herrera R1, Preciado Pérez S1, Gómez de la Torre A1, Lumbreras González E1, Kamila, Sánchez-Guijo Martín F1, Diez Campelo M1. 1. Servicio de Hematología, Hospital Universitario de Salamanca-IBSAL, Salamanca 2. Servicio de Hematología, Hospital Reina Sofía de Córdoba
